S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
S&P 500   4,554.89 (+0.10%)
DOW   35,416.98 (+0.24%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Addex Therapeutics (ADXN) News Today

$5.69
-0.04 (-0.70%)
(As of 11/28/2023 ET)
Compare
Today's Range
$5.16
▼
$5.76
50-Day Range
$5.26
▼
$8.52
52-Week Range
$5.10
▼
$45.60
Volume
4,882 shs
Average Volume
13,656 shs
Market Capitalization
$4.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media
SourceHeadline
finance.yahoo.com logoAddex Convenes Extraordinary General Meeting
finance.yahoo.com - November 28 at 3:01 AM
MarketBeat logoAddex Therapeutics (ADXN) Set to Announce Quarterly Earnings on Wednesday
americanbankingnews.com - November 27 at 1:40 AM
finance.yahoo.com logoAddex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
finance.yahoo.com - November 23 at 9:24 AM
finance.yahoo.com logoAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
finance.yahoo.com - November 14 at 8:37 AM
finance.yahoo.com logoAddex Announces Participation in the Bio-Europe 2023 Conference
finance.yahoo.com - November 2 at 10:28 AM
finanznachrichten.de logoAddex Therapeutics: Addex Completes ADS Ratio Change
finanznachrichten.de - October 21 at 2:34 PM
finance.yahoo.com logoAddex Completes ADS Ratio Change
finance.yahoo.com - October 20 at 1:42 AM
markets.businessinsider.com logoAddex To Implement ADS Ratio Change
markets.businessinsider.com - October 6 at 7:15 PM
finance.yahoo.com logoAddex Therapeutics focused on securing new partnerships to fund promising treatments
finance.yahoo.com - October 5 at 2:15 PM
markets.businessinsider.com logoH.C. Wainwright Reaffirms Their Hold Rating on Addex Therapeutics (ADXN)
markets.businessinsider.com - September 25 at 11:16 AM
finance.yahoo.com logoAddex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
finance.yahoo.com - September 6 at 2:57 AM
benzinga.com logoAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
benzinga.com - September 5 at 2:55 AM
finance.yahoo.com logoAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
finance.yahoo.com - September 5 at 2:55 AM
finance.yahoo.com logoAddex’s Dipraglurant Development in Post-Stroke Recovery Supported by Data Published in Brain
finance.yahoo.com - September 4 at 1:35 AM
finanznachrichten.de logoAddex Therapeutics: Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
finanznachrichten.de - August 10 at 9:45 AM
finance.yahoo.com logoAddex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 10 at 9:45 AM
markets.businessinsider.com logoWhat Wall Street expects from Addex Therapeutics's earnings
markets.businessinsider.com - August 9 at 7:09 PM
finance.yahoo.com logoAddex Therapeutics to Release Half-Year 2023 Financial Results and Host Conference Call on August 10, 2023
finance.yahoo.com - August 4 at 2:00 AM
finance.yahoo.com logoAddex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration
finance.yahoo.com - August 3 at 7:47 AM
finanznachrichten.de logoAddex Therapeutics: Addex Shareholders Approve All Resolutions at Annual General Meeting
finanznachrichten.de - June 1 at 9:52 AM
msn.com logoEarnings Scheduled For May 11, 2023
msn.com - May 11 at 4:42 PM
finance.yahoo.com logoAddex Reports Q1 2023 Financial Results and Provides Corporate Update
finance.yahoo.com - May 11 at 4:44 AM
finance.yahoo.com logoAddex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study
finance.yahoo.com - May 10 at 3:40 AM
finance.yahoo.com logoAddex Convenes Annual General Meeting 2023
finance.yahoo.com - May 5 at 3:58 AM
finance.yahoo.com logoAddex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023
finance.yahoo.com - May 4 at 2:53 AM
finanznachrichten.de logoAddex Therapeutics: Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson's Disease
finanznachrichten.de - April 4 at 8:41 AM
finance.yahoo.com logoAddex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease
finance.yahoo.com - April 4 at 1:21 AM
finance.yahoo.com logoAddex Raises $5.0 Million in Equity Financing
finance.yahoo.com - April 3 at 5:18 AM
finance.yahoo.com logoAddex Reports Full Year 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - March 30 at 1:35 AM
finance.yahoo.com logoAddex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023
finance.yahoo.com - March 28 at 8:59 AM
finance.yahoo.com logoAddex Announces Upcoming Conferences it will participate for H1 2023
finance.yahoo.com - March 16 at 9:30 AM
seekingalpha.com logoADXN Addex Therapeutics Ltd
seekingalpha.com - March 1 at 6:38 PM
finanznachrichten.de logoAddex Therapeutics: Addex Regains Nasdaq Listing Compliance
finanznachrichten.de - February 9 at 6:31 PM
finance.yahoo.com logoAddex Regains Nasdaq Listing Compliance
finance.yahoo.com - February 9 at 1:19 AM
finanznachrichten.de logoAddex Therapeutics: Addex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1
finanznachrichten.de - February 6 at 7:16 AM
finance.yahoo.com logoAddex Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1
finance.yahoo.com - February 6 at 1:41 AM
seekingalpha.com logoAddex rises 10% on extended research pact with Indivior to develop substance use disorder drugs
seekingalpha.com - December 8 at 6:59 AM
finance.yahoo.com logoAddex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration
finance.yahoo.com - December 8 at 1:58 AM
seekingalpha.com logoAddex Therapeutics Ltd (ADXN) Q3 2022 Earnings Call Transcript
seekingalpha.com - November 14 at 12:37 AM
finanznachrichten.de logoAddex Therapeutics: Addex Reports Q3 2022 Financial Results and Provides Corporate Update
finanznachrichten.de - November 12 at 8:22 AM
finance.yahoo.com logoAddex Reports Q3 2022 Financial Results and Provides Corporate Update
finance.yahoo.com - November 11 at 5:20 AM
247wallst.com logoTim Dyer Ups Take in Addex Therapeutics Ltd (ADXN) to over 20%
247wallst.com - November 10 at 2:18 PM
finance.yahoo.com logoAddex Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
finance.yahoo.com - November 3 at 3:10 AM
finance.yahoo.com logoAddex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022
finance.yahoo.com - November 3 at 3:10 AM
finance.yahoo.com logoAddex to Present at the Sachs Associates 22nd Annual Biotech in Europe Forum & Baader Investment Conference
finance.yahoo.com - September 20 at 3:47 AM
benzinga.com logoAddex Reports 2022 Half Year and Second Quarter...
benzinga.com - August 19 at 9:52 PM
finance.yahoo.com logoAddex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
finance.yahoo.com - August 18 at 9:37 AM
finance.yahoo.com logoAddex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance Use Disorders
finance.yahoo.com - August 15 at 6:52 PM
finance.yahoo.com logoAddex Therapeutics to Report Half-Year 2022 Financial Results and Host Conference Call on August 18, 2022
finance.yahoo.com - August 12 at 5:26 AM
finance.yahoo.com logoAddex Completes $4.2 Million Equity Financing
finance.yahoo.com - July 26 at 8:21 PM
Get Addex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter.



ADXN Media Mentions By Week

ADXN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADXN
News Sentiment
▼
0.63

0.86
▲
Average
Medical
News Sentiment

ADXN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADXN Articles
This Week
▼
5

0
▲
ADXN Articles
Average Week

Get Addex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADXN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:ADXN) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -